Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Kaiser Pushes Back on REMS: Acorda Listens; Will FDA?

Feb 01 2010

• By Michael McCaughan

Related Content

Allergan's Botox Off-Label Promotion Suit Raises Questions, But Why Would Wall Street Care?

Oct 01 2009

Waking Up to REMS (Part 3): Redefining Marketing

Sep 01 2009

The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two

Sep 01 2009

FDA Amendments Act: More Regulation = More Comfort and More Products

Oct 01 2007

The Opioid REMS: Health Care Reform, One Class at a Time

Feb 01 2010

The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities

Feb 01 2009

Related Companies

Acorda Therapeutics, Inc.

Elan Corporation

Biogen, Inc.

Additional Topics

Leadership Regulation Reimbursement BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window